Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
The system is powered by BrainSense technology, which has received approval from USFDA
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
